PTO-Form 1449

FEB 1 7 2004

ATTY DOCKET NO. APPLICATION NO 42837-2001021 10/748,089

APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

GROUP

December 29, 2003

Not yet assigned

## **U.S. PATENT DOCUMENTS**

EXAMINER							FILING DAT
INITIAL	<del> </del>	DOCUMENT NUMBER	DATE	Okamoto, et al.	CLASS	SUBCLASS	APPROPRIA
(V)		4,018,913	04/19/77	(equiv to DE 2655636)	514	28	
0	2.	4,018,915	04/19/77	Okamoto, et al. (equiv to DE 2655636)	514	20	
	3.	4,036,955	07/10/77	Okamoto, et al. (equiv to DE 2655636)	514	20	
	4.	4,041,156	08/09/77	Okamoto, et al. (equiv to DE 2655636)	514	w	
	5.	4,046,876	09/06/77	Okamoto, et al. (equiv to DE 2655636)	514	20	f
	6.	4,055,651	10/25/77	Okamoto, et al. (equiv to DE 2655636)	514	319	
	7.	4,055,636	10/25/77	Okamoto, et al. (equiv to DE 2655636)	514	20	
	8.	4,070,457	01/24/78	Okamoto, et al. (equiv to DE 2655636)	514	510	
	9.	4,073,914	02/14/78	Kikumoto, et al. (equiv to DE 2655636)	514	319	
	10.	4,085,057	04/18/78	Masuda, et al.	430	108.51	
	11.	4,096,255	06/20/78	Kikumoto, et al. (equiv to DE 2655636)	514	227.5	
	12.	4,104,392	08/01/78	Okamoto, et al. (equiv to DE 2655636)	514	307	
	13.	4,438,122	03/20/84	Holmwood, et al.	514	277	
	14.	4,505,910	03/19/85	Bagli	514	26	
	15.	4,518,600	05/21/85	Holmwood, et al.	514	256	
	16.	4,544,402	10/01/85	Schnurbusch, et al.	504	232	
	17.	4,559,345	12/17/85	Gomarasca, et al.	514	275	
	18.	4,672,065	06/09/87	Spatz	314	255.00	
	19.	4,908,368	03/13/90	Murase, et al.	514	256	
	20.	4,959,364	09/25/90	Mueller, et al.	SIA	237.5	
	21.	4,992,439	02/12/91	Meanwell	514	247	
	22.	5,030,644	07/09/91	Baldwin, et al.	514	343	
	23.	5,120,734	06/09/92	Klausener, et al.	514	252.63	
	24.	5,238,934	08/24/93	Knuppel, et al.	5121	241	
	25.	5,278,184	01/11/94	Artico, et al.	514	423	
	26.	5,510,332	04/23/96	Kogan, et al.	514	14	
1	27.	5,580,868	12/03/96	Lunkenheimer, et al.	514	222.5	
N/	28.	5,770,573	06/23/98	Arrhenius, et al.	460	52	W
X 1/2	29.	5,814,643	09/29/98	Duggan, et al.	514	89	<u>_</u>

July 1 2/16/01

(Use several sheets if necessary)

INFORMATION DISCLOSURE CITATION

PTO-Form 1449

(Use several sheets if necessary)

ATION 5004 S

ATTY DOCKET NO. 42837-2001021

10/748.089

**APPLICANT** 

Andrei W. KONRADI, et al.

FILING DATE

GROUP

December 29, 2003

Not yet assigned

. (				HADE	Sheet 2 of
(XV)	30.	5,861,429	01/19/99	Sato, et al.	514 456
2	31.	5,925,644	07/20/99	Jakobi, et al.	314 264
	32.	5,942,504	08/24/99	Grobelny.	514 218
	33.	5,955,491	09/21/99	Sohda, et al.	514 215
	34.	5,962,479	10/05/99	Chen	514 348
	35.	5,972,946	10/26/99	Murata, et al.	514 256
	36.	6,005,117	12/21/99	Wehner, et al.	514 3325
717	37.	2002/0052375	05/02/02	Konradi, et al.	514 252.68
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	38.	2002/0055509	05/09/02	Konradi, et al.	514 248
87	39.	2003/0144328	07/31/03	Konradi, et al.	514 365

## FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO Canada 40. 07/03/77 2,241,149 (equiv to DE 19548709) Canada 41. 2,259,224 01/08/78 (equiv to DE 19654483) 42. 0 116 494 08/1984 Europe 43. 0 147 211 07/03/93 Europe 44. 0 288 176 10/26/88 Europe 45. 0 330 506 A2 08/30/89 Europe 46. 0 330 506 A3 08/30/89 Europe 47. 0 526 348 02/03/93 Europe 48. 0 535 521 04/07/93 Europe Germany 49. 19548709 07/03/97 (equiv to CA 2,241,149) 50. 19536891 04/1997 Germany Germany 51. 19654483 01/02/98 (equiv to CA 2,259,224) 52. 19713000 10/01/98 Germany (Abstract) Germany 53. (US equiv are all Okamoto and Kikumoto 2655636 06/23/77 US patents listed above) **Great Britain** 54. 1500063 02/08/78 (equiv to HU 169926) Hungary 55. 169926 09/28/76 (equiv to GB 150063) 56. 59212480 12/1984 Japan (Abstract) **57.** 92/16549 10/01/92 **WIPO 58.** 93/12809 07/08/93 WIPO 59. 96/01644 **WIPO** 01/25/96

July 3/20/02

PTO-Form 1449	•
INFORMATION DISCLOSU (Use several sheets if ne	JRE CITATION Cocessery) FEB 17 2004 3

ATTY DOCKET NO. 42837-2001021

APPLICATION NO 10/748,089

APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

GROUP

December 29, 2003

Not yet assigned

0 /					· · · · · · · · · · · · · · · · · · ·	,		Sheet	: 3 c	<u>of 5</u>
X18	60.	96/22966	08/01/96	WIPO						
	61.	96/32383	04/1997	WIPO					Ш	_
,	62.	97/23451	07/03/97	WIPO					Ш	
	63.	98/00395	01/08/98	WIPO					Ш	_
	64.	98/33783	12/03/98	WIPO					Ш	
	65.	98/53814	12/03/98	WIPO (Abstract)						
	66.	98/53817	08/06/98	WIPO			$oxed{oxed}$		Ш	
	67.	99/06431	02/11/99	WIPO						
	68.	99/06432	02/11/99	WIPO					Ш	
	69.	99/06433	02/11/99	WIPO			Ш		Ц	
	70.	99/06390	02/11/99	WIPO					Ш	
	71.	99/06391	02/11/99	WIPO					Ш	
	72.	99/10312	03/04/99	WIPO			Ш		Ц	$\Box$
	73.	99/10313	03/04/99	WIPO					Ш	
7	74.	99/37605	07/29/99	WIPO					Ц	
	75.	99/37618	07/29/99	WIPO		17	14		×	$\square$
Wo/	76.	99/52898	10/21/99	WIPO		7	$\Gamma_{\Lambda}$	-		

		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
80	<del>1</del> 7.	Abraham, et al. "Alpha4-Integrins Mediate Antigen-Induced Late Bronchial Responses and Prolonges Airway Hyperresponsiveness in Sheep," J. Clin. Invest. 93: 776-787 (1994).
9	78.	Advani, S.B., et al. "Potential Antineoplastic Agents: N-(1-Benzoxazolyl)amino Acid Esters," <i>J. Pharm. Sci.</i> 57(10): 1693-1696 (1968).
	79.	Bao, et al. "Correlation of VLA-4 Integrin Expression with Metastatic Potential in Various Human Tumor Cell Lines," Diff. 52: 239-246 (1993).
8	80.	Baron, et al. "Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma," <i>J. Exp. Med.</i> 177: 57-68 (1993).
1	81.	Baron, et al. "The Pathogensis of Adoptive Murine Autoimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1," <i>J. Clin. Invest.</i> 93: 1700-1708 (1994).
1	82.	Burkly, et al. "Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigen-4 Integrin," <i>Diabetes</i> 43: 529-534 (1994).
1	83.	Cybulsky, et al. "Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule during Atherogenesis," Science 251: 788-791 (1991).
1	84.	Elices, et al. "Expression and Functional Significance of Alternatively Spliced CS1 Fibronectin in Rhematoid Arthritis Microvasculature," <i>J. Clin. Invest.</i> 93: 405-416 (1994).
1	85.	Elices, et al. "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrim VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site," Cell 60: 577-584 (1990).
1	86.	Gordeev, M.F., et al. "Combinatorial Approaches to Pharmacophoric Heterocycles: A Solid-Phase Synthesis of 3,1-Benzoxazine-4-ones," "Biotech. And Bioengineering 61(1): 13-16 (1998).
77	87.	Hamann, et al. "Role of α4-Integrins in Lymphocyte Homing to Mucosal Tissues <i>In Vivo</i> ," <i>J. Immunol.</i> 152: 3283-3292 (1994).
848	88.	Henke, B.R., et al. "N-(2-Benzoylphenyl)-L-tyrosine: Aryl Agonists. Disclovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents," <i>J. Med. Chem.</i> 41(25): 5020-5036 (1998).

Sudhih 126/

PT	٦.F	orm	14	49

INFORMATION DISCLOSURE CHATION (Use several sheets if necessary)

ATTY DOCKET NO. 42837-2001021 APPLICATION NO 10/748,089

APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

GROUP

December 29, 2003

Not yet assigned

		Sheet 4 of 5
Charles	<b>X</b> 9.	Hladon, B., et al. "In Vitro cytostatic activity of some amino acid 4-N-substitied cytosines," Arch. Immunol. Ther. Exp. 40(2): 145-150 (1992 (Abstract)
2 7	90.	Hoffman, S., et al. "N-Pyrimidinylamino acids, III. N-(oxopyrimidinyl) derivatives of neutral amino acids, Z. Chem. 12(1): 21-22 (1972). CODEN: ZEACEAL. (Abstract).
	91.	Jaeger, et al. <i>Chem. Berichte</i> . 101(8): 2762-2770 (1968). Chem. Abstract 69: 676 Kawaguchi, et al. "VLA-4 Molecules on Tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface," <i>Jap. J. Canc. Res.</i> 83: 1304-1316 (1992).
	92.	Lauri, et al. "Decreased Adhesion to Endothelial Cells and Matrix of H-2k <sup>b</sup> Gene Transfected Tumor Cells," <i>Br. J. Canc.</i> 68: 862-867 (1993).
	93.	Lazer, E. S., et al. "Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action," <i>J. Med. Chem.</i> 37(7): 913-923 (1994).
	94.	Li, et al. "An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leukocyte Adhesion Molecule in Rabbit Aortic Endothelium," <i>Arteriosclr. Thromb.</i> 13: 197-204 (1993).
	95.	Ma, D., et al. "Accelerating Effect Induced by the Structure of α-Amino Acid in the Copper Catalyzed Coupling Reaction of Aryl Halides with α-Amino Acids. Synthesis of Benzolactam-V8," <i>J. Am. Chem.</i> Soc. 120(48): 12459-12467 (1998).
	96.	Marr-Leisy, et al. Colloid and Polymer Sc. 263(10): 791-798 (1985). Chem. Abstract 105: 97885
	97.	Mulligan, et al. "Role of β1, β1 Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes," <i>Immunology</i> 150: 2407-2417 (1993).
	98.	Ohta, et al. Heterocycles 31(9): 1655-1662 (1990). Chem. Abstract 114: 101454-1991:101454
	99.	Ohta, et al. Chem. & Pharmaceutical Bulletin 27(12): 2980-2987 (1979). Chem. Abstract 93: 46584-1980: 446584
	100.	Okahara, et al. "Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1 (VCAM-1) in Tumor Necrosis Factor a Enhancement of Experimental Metastasis," Can. Res. 54: 3233-3236 (1994).
	101.	Osborn. "Leukocyte Adhesion to Endothelium in Inflammation," Cell 62: 3-6 (1990).
	102.	Paavonen, et al. "In Vivo Evidence of the Role fo α4β1-VCAM-1 Interaction in Sarcoma, but not in Carcinoma Extravasation," Int. J. Can. 58: 298-302 (1994).
	103.	Paul, et al. "Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts," <i>Transpl. Proceed.</i> 25: 813-814 (1993).
	104.	Postigo, et al. "Increased Binding of Synovial T-Lynmphocytes from Rheumatoid Arthritis to Endothelial-Leukocyte Adhesion Molecule-1 (ELAN-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1)," J. Clin. Invest. 89: 1445-1452 (1992).
	105.	Pretolani, et al. "Antibody to Very Late Activation Antigen 4 Prevents Antigen-induced Bronchial Hyperreactivity and Cellular Infiltration in the Guinea Pig Airways," J. Exp. Med. 180: 795-805 (1994).
	106.	Sasseville, et al. "Monocyte Adhesion to Endothelium in Simian Immunodeficiency Virus-Induced AIDS Encephalitis is Mediated by Vascular Cell Adhesion Molecule-1/α4β1 Integrin Interactions," <i>Am. J. Path.</i> 144: 27 (1994).
	107.	Schadendorf, et al. "Tumor Progression and Metastatic Behavior In Vivo Correlates with Integrin Expression in Melanocytic Tumores," J. Path. 170: 429-434 (1993).
	108.	Simchowitz, et al. <i>J. Biol. Chem.</i> 265(23): 13457-13463-1990:530558
	109.	Springer, et al. "Adhesion Receptors of the Immune System," Nature. 346: 425-434 (1990).
	110.	Teranishi, K., et al. "Synthesis and Chemiluminescense of Coelenterazine (Oplophorus Luciferin) Analogs," Bull. Chem. Soc., Jpn. 63(11): 3132-3140 (1990).
7	111. Oc	van Dinther-Janssen, et al. "Role of the CS1 Adhesion Motif of Fibronectin in T Cell Ahesion to Synovial Membrane and Peripheral Lymph Node Endothelium," <i>Annals. Rheumatic Dis.</i> 52: 672-676 (1993).
800	<b>A</b> 12,	van Dinther-Janssen, et al. "The VLA-4/VCAM-1 Pathway is Involved in Lymphocyte Adhesion to Endothelium in Theumatoid Synovium," <i>J. Immunology</i> . 147: 4207-4210 (1991).

PTO-Form 1449

INFORMATION DISCLOSURE CITATION REPLICATION NO 42837-2001021 10/748,089

APPLICANT Andrei W. KONRADI, et al.

FILING DATE December 29, 2003 Not yet assigned

Sheet 5 of 5

The provided of Neutrophils in Generalized Reperfusion Injury Associted with Resuscitation from Shock," Surgery 106: 509-516 (1989).

114. Yang, et al. "Inhibition of Insultitis and Prevention of Diabetes in Nonobese Diabetic Mice by Blocking

(mg   113.	Vedder, et al. "Role of Neutrophils in Generalized Reperfusion Injury Associted with Resuscitation
	from Shock," Surgery 106: 509-516 (1989).
m 114.	Yang, et al. "Inhibition of Insultitis and Prevention of Diabetes in Nonobese Diabetic Mice by Blocking
	L-Selectin and Very Late Antigen 4 Adhesion Recptors," Proc. Natl. Acad. Sci. (USA) 90: 10494-
	10498 (1993).
115.	Yednock, et al. "Prevention of Experimental Autommune Encephalomyelitis by Antibodies Against
	α4β1 Integrin," Nature 356: 63-66 (1992).
	1 1

**EXAMINER** 

pull hold

DATE CONSIDERED

7/26/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.